Read the recent article in Seeking Alpha posted here. The writer did an interview with Hermo Pharma which is the company that recently challenged Amarantus (AMBS) patents on MANF.
"At this time the only publicly traded company that is playing in this field is Amarantus (AMBS.OB). Amarantus owns sequence patents on MANF which were upheld in court after Hermo Pharma challenged them. As Henri mentioned, they challenged the patents because they believed that they covered too many possible variants of the protein and it therefore "causes "an undue burden" to anyone who would like to test these variants for activity". The only way I can interpret this is that anyone looking to test different variants of MANF will be forced to go through AMBS as it has patents "that cover all sequences with 90% homology to MANF"."
GDNF was purchased by Amgen for $250 million when it was still in animal testing (ie before phase 1) and MANF has had much better results than GDNF at this stage. This market cap is way too small.
Jennifer - It's all about the patents here. They're worth a helluva lot more than $8 Million. You don't get the co-founder of Amgen on board just because he likes the CEO. They have some valuable assets here. We're going to have some continued selling by weak hands that are just glad to get out at breakeven. Then it will move much higher.
I don't think people understand how valuable this is. Amgen spent over $300 Million on GDNF but gave up on it because of delivery methods. GDNF was and still is in trials on Parkinson. Gill University is going through phase II trials and the major impediment has been that GDNF and other neurotrophic factors like it can't be delivered easily to the brain. However, as the partner from Hermo Pharma in the article I referenced above from Seeking Alpha said, Gill Univ has made some major strides on the delivery method.
The best part, though, is that MANF has shown much better results comparatively at the stage in development it is at versus what GDNF showed at similar stages. Since AMBS has such strong patent protection on MANF and the deliver methods are vastly improved over when GDNF was originally in human trials, its kind of ridiculous that AMBS is trading at only $7 Million. Their patents alone are potentially worth HUNDREDS of MILLIONS.
I totally agree. People will be impatient along the way given how volatile the stock was in the past month so you will get bouts of selling but the valuation here is quite low when you look at the patent protection AMBS has on MANF and at the positive data compared to GDNF at similar stages.
I think with the help of Dr. Rubinfeld (co-founder of Amgen that is a director for AMBS) they should be able to monetize the patents. You don't get him and a few other buys with big pharma experience from Bayer and Bristol Myers on board without MANF having some significant potential. Should be fun to watch. Something with as much promise as MANF and with patent protection, even if it's in pre-clinical trial status, should be worth at least $50 to $75 Million in the open market. I believe the copany is working toward a joint venture/partnership to get MANF to trial. I highly doubt you will see this worth anywhere near $7 Million for much longer.